RESEARCH MONOGRAPH · KDC-MN-384

Higenamine

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

46/100

Botanical beta-2 agonist with a doping-control problem and not much else to recommend it

Higenamine, also called norcoclaurine, is a benzyltetrahydroisoquinoline alkaloid found in plants like Nandina domestica and Aconitum japonicum, and it's a relatively selective beta-2 adrenergic agonist with weak beta-1 and minimal alpha activity. It got popularized in fat-burner supplements around 2015 as 'natural clenbuterol,' which is mostly marketing and partly true: it does activate the same beta-2 pathway, just less potently and with lower bioavailability.

The pharmacology has been studied mostly by Asian groups since higenamine has historical use in traditional medicine for cardiovascular indications. The receptor binding data is decent, IC50 in the low micromolar range at beta-2, weaker activity elsewhere. Lipolytic and bronchodilator effects in cell and animal models are reproducible. The translational data in humans is thin.

Here's the practical problem: WADA banned higenamine in 2017 as a beta-2 agonist, and it shows up in athlete tests with depressing frequency because supplement labels often don't disclose it. So if anyone in your circle competes drug-tested, this is a compound to know exists specifically because they shouldn't be near it accidentally.

For research applications it's a tool compound for beta-2 selective work in cellular and ex vivo systems where you want a botanical-source alkaloid for some reason. Otherwise clenbuterol or formoterol are cleaner reference agonists with better pharmacology.

What we don't like is the cardiac arrhythmia signal. There are case reports of higenamine-containing supplements being associated with tachycardia and palpitations, which is unsurprising given the beta-receptor activity but is worth flagging because the supplement doses are not always well controlled.

Sourcing as research-grade material is fine, higenamine is a small molecule with straightforward synthesis or extraction, HPLC purity from competent suppliers is reliable. The catch is botanical-extract sourcing where stereochemistry and contamination with other alkaloids is variable.

Honestly there's not much research case for using higenamine over a better-characterized beta-2 agonist, and the regulatory baggage in human studies is significant.

Evidence: 35
Mechanism: 60
Reliability: 45
Safety: 50
Sourcing: 55
Value: 50
Signal: 35
Staying power: 40

Plain-language summary Intrigue 38 / 100

Higenamine is a benzylisoquinoline alkaloid found in lotus, aconite, and several traditional Chinese medicine herbs. It acts as a beta-2-preferring adrenergic agonist (with weaker beta-1 activity), giving it a pharmacological profile loosely similar to clenbuterol but at much lower potency. Marketed in pre-workout supplements for vasodilation and mild stimulant effects. WADA banned it in competition. The plasma half-life is extremely short, on the order of 6 to 18 minutes, which limits how long any effect lasts. The actual clinical evidence in humans is sparse and the supplement industry uses are mostly extrapolated from beta-agonist class effects. Botanical beta-adrenergic reference compound. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Beta-2 adrenergic agonist (botanical)

A benzylisoquinoline alkaloid found in lotus and aconite; a beta-2 adrenergic agonist used in pre-workout supplements.

Abstract

Higenamine ((R/S)-1-(4-hydroxybenzyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol; CAS 5843-65-2; molecular formula C16H17NO3; molecular weight 271.31) is a benzylisoquinoline alkaloid found in Aconitum, Tinospora cordifolia, Nelumbo nucifera (lotus), and other plants. The compound is a beta-2-preferring adrenergic agonist with secondary beta-1 and limited beta-3 activity; the agonist profile is qualitatively similar to clenbuterol with substantially lower potency. Used in traditional Chinese medicine for cardiac and respiratory indications. Marketed as a pre-workout supplement ingredient for vasodilation and mild stimulant effects. WADA-banned in competition. Plasma half-life is approximately 0.1 to 0.3 hours, very short. Used as a botanical beta-adrenergic agonist in research.

Mechanism of action

Beta-2-preferring adrenergic agonist with secondary beta-1 activity; mechanism comparable to clenbuterol with lower potency.

Reported research dose ranges

Reported research dose ranges vary across the published literature.

References

Lo CF, Chen CM. Pharmacokinetic studies of higenamine in rabbit plasma. Drug Metab Dispos 1996.
Tsukiyama M, et al. Beta-2-adrenoceptor-mediated tracheal relaxation induced by higenamine. Biol Pharm Bull 2009.
Cohen PA, et al. Pharmaceutical quantities of higenamine in Coleus extracts. Forensic Sci Int 2019.

Read the full monograph

Available as a research-use-only PDF download.

KDC-MN-384

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Higenamine

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs